Table 1 Baseline clinicopathological characteristics of studied endometrial cancers cohorts
|  | Entire Cohort N = 342 | Group A N = 215 | Group B N = 127 | p * |
|---|---|---|---|---|
Histology | Endometrioid and non-endometrioid endometrial cancers | Low- and moderate- grade endometroid endometrial cancer | Non-endometrioid and high-grade endometroid endometrial cancer | |
Age [years] (mean ± SD**) | 67.424 ± 8.399 | 65.167 ± 6.661 | 71.244 ± 9.599 | < 0.0001# |
BMI [kg/m2] (mean ± SD**) | 24.945 ± 3.195 | 25.774 ± 3.488 | 23.542 ± 1.952 | < 0.0001# |
Stage*** | < 0.0001# | |||
 1 | 174 (50.88%) | 133 (61.86%) | 41 (32.28%) | |
 2 | 93 (27.19%) | 45 (20.93%) | 48 (37.80%) | |
 3 | 71 (20.76%) | 35 (16.28%) | 36 (28.35%) | |
 4 | 4 (1.17%) | 2 (0.93%) | 2 (1.57%) | |
Grade | < 0.0001# | |||
 1 | 90 (26.31%) | 90 (41.86%) | 0 (0.00%) | |
 2 | 132 (38.60%) | 125 (58.14%) | 7 (5.51%) | |
 3 | 120 (35.09%) | 0 (0.00%) | 120 (94.49%) | |
MI*** ≥ 50% | 258 (75.44%) | 148 (68.84%) | 110 (86.61%) | 0.0002# |
+LN& | 40 (11.70%) | 15 (7.44%) | 25 (19.68%) | 0.0004# |
+LVSI&& | 94 (27.49%) | 42 (19.53%) | 52 (40.94%) | < 0.0001# |
+MELF&&& | 18 (5.26%) | 18 (8.37%) | 0 (0.00%) | < 0.0001# |
Adjuvant therapy | < 0.0001# | |||
 VBTHA | 175 (51.17%) | 107 (49.77%) | 68 (53.54%) | |
 ERTHB | 26 (7.61%) | 0 (0.00%) | 26 (20.47%) | |
 CHTC | 33 9.65%) | 32 (14.88%) | 1 (0.79%) | |
 HTHD | 2 (0.58%) | 2 (0.92%) | 0 (0.00%) | |
 VBTHA + ERTHB | 10 (2.92% | 0 (0.00%) | 10 (7.87%) | |
 ERTHB + CHTC | 25 (7.31%) | 3 (1.39%) | 22 (17,33%) | |
 none | 71 (20.76%) | 71 (33.04%) | 0 (0.00%) | |
Recurrence | 46 (13.45%) | 20 (9.30%) | 26 (20.47%) | 0.0034# |